JP2016053040A5 - - Google Patents

Download PDF

Info

Publication number
JP2016053040A5
JP2016053040A5 JP2015201153A JP2015201153A JP2016053040A5 JP 2016053040 A5 JP2016053040 A5 JP 2016053040A5 JP 2015201153 A JP2015201153 A JP 2015201153A JP 2015201153 A JP2015201153 A JP 2015201153A JP 2016053040 A5 JP2016053040 A5 JP 2016053040A5
Authority
JP
Japan
Prior art keywords
relaxin
risk
mortality
composition
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015201153A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016053040A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016053040A publication Critical patent/JP2016053040A/ja
Publication of JP2016053040A5 publication Critical patent/JP2016053040A5/ja
Pending legal-status Critical Current

Links

JP2015201153A 2008-05-16 2015-10-09 急性心不全に伴う呼吸困難のリラキシンによる治療 Pending JP2016053040A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US61/127,889 2008-05-16
US19054508P 2008-08-28 2008-08-28
US61/190,545 2008-08-28
US20124008P 2008-12-08 2008-12-08
US61/201,240 2008-12-08
US16433309P 2009-03-27 2009-03-27
US61/164,333 2009-03-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014165276A Division JP5875646B2 (ja) 2008-05-16 2014-08-14 急性心不全に伴う呼吸困難のリラキシンによる治療

Publications (2)

Publication Number Publication Date
JP2016053040A JP2016053040A (ja) 2016-04-14
JP2016053040A5 true JP2016053040A5 (enExample) 2016-07-07

Family

ID=40834101

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011509783A Expired - Fee Related JP5651586B2 (ja) 2008-05-16 2009-05-15 急性心不全に伴う呼吸困難のリラキシンによる治療
JP2012200728A Expired - Fee Related JP5638044B2 (ja) 2008-05-16 2012-09-12 急性心不全に伴う呼吸困難のリラキシンによる治療
JP2014165276A Expired - Fee Related JP5875646B2 (ja) 2008-05-16 2014-08-14 急性心不全に伴う呼吸困難のリラキシンによる治療
JP2015201153A Pending JP2016053040A (ja) 2008-05-16 2015-10-09 急性心不全に伴う呼吸困難のリラキシンによる治療

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2011509783A Expired - Fee Related JP5651586B2 (ja) 2008-05-16 2009-05-15 急性心不全に伴う呼吸困難のリラキシンによる治療
JP2012200728A Expired - Fee Related JP5638044B2 (ja) 2008-05-16 2012-09-12 急性心不全に伴う呼吸困難のリラキシンによる治療
JP2014165276A Expired - Fee Related JP5875646B2 (ja) 2008-05-16 2014-08-14 急性心不全に伴う呼吸困難のリラキシンによる治療

Country Status (30)

Country Link
US (7) US8053411B2 (enExample)
EP (2) EP2288373B1 (enExample)
JP (4) JP5651586B2 (enExample)
CN (3) CN102036679A (enExample)
AR (1) AR071810A1 (enExample)
AU (1) AU2009246114B2 (enExample)
BR (1) BRPI0913011A2 (enExample)
CA (1) CA2724540C (enExample)
CR (1) CR11749A (enExample)
CY (1) CY1116925T1 (enExample)
DK (1) DK2288373T3 (enExample)
EA (2) EA201500552A1 (enExample)
ES (1) ES2546287T3 (enExample)
GB (2) GB2459983B (enExample)
HK (1) HK1202054A1 (enExample)
HR (1) HRP20150845T1 (enExample)
HU (1) HUE025483T2 (enExample)
IL (3) IL208992A (enExample)
MA (1) MA32389B1 (enExample)
MX (1) MX2010012450A (enExample)
MY (2) MY159803A (enExample)
NZ (3) NZ701038A (enExample)
PL (1) PL2288373T3 (enExample)
PT (1) PT2288373E (enExample)
SG (2) SG191587A1 (enExample)
SI (1) SI2288373T1 (enExample)
TW (1) TWI386202B (enExample)
UA (1) UA99953C2 (enExample)
WO (1) WO2009140659A2 (enExample)
ZA (1) ZA201007449B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5651586B2 (ja) * 2008-05-16 2015-01-14 コーセラ,インコーポレーテッド 急性心不全に伴う呼吸困難のリラキシンによる治療
RU2512933C2 (ru) * 2008-05-16 2014-04-10 Кортера, Инк. Способ лечения хронической сердечной недостаточности
CN102883742B (zh) * 2010-03-10 2014-09-24 佛罗里达大学研究基金会有限公司 用松弛素调节水孔蛋白
CA2802273A1 (en) * 2010-08-06 2012-02-09 Pronota N.V. Perlecan as a biomarker for renal dysfunction
EP3572091B1 (en) 2010-08-17 2023-12-13 Ambrx, Inc. Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
RU2014103288A (ru) * 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
WO2013059879A1 (en) * 2011-10-26 2013-05-02 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
JP6562632B2 (ja) * 2012-02-14 2019-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 心血管疾患および他の状態のためのパラクリン遺伝子の全身送達および制御された発現
US9452973B2 (en) 2012-05-04 2016-09-27 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Modulators of the relaxin receptor 1
CN110840890A (zh) * 2012-10-26 2020-02-28 凯西制药公司 用于在心力衰竭中控制血压和减轻呼吸困难的方法
EP2981258B8 (en) * 2013-04-05 2020-11-11 scPharmaceuticals Inc. Pharmaceutical formulations for subcutaneous administration of furosemide
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
PE20161133A1 (es) * 2014-02-03 2016-11-08 Novartis Ag Filtros para equipos de infusion
EP2946788A1 (en) 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
RU2016147122A (ru) * 2014-06-13 2018-07-16 Новартис Аг Применение серелаксина для снижения gdf-15
PT3387019T (pt) 2015-12-09 2022-01-14 Scripps Research Inst Proteínas de fusão de imunoglobulina de relaxina e métodos de uso
CN108697330B (zh) 2016-02-12 2022-07-15 心脏起搏器股份公司 用于患者监视的系统和方法
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
US11832970B2 (en) 2017-07-26 2023-12-05 Cardiac Pacemakers, Inc. Worsening heart failure stratification
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
ES3041602T3 (en) 2018-12-10 2025-11-13 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
ES3058386T3 (es) 2019-01-04 2026-03-10 Sq Innovation Ag Composiciones farmacéuticas de furosemida
US12397005B2 (en) 2019-01-04 2025-08-26 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
JP7465881B2 (ja) 2019-01-31 2024-04-11 エスシーファーマシューティカルズ インコーポレイテッド フロセミドの濃縮液体医薬製剤及びそれを投与する方法
JP2025528469A (ja) 2022-08-31 2025-08-28 リラクセラ ファルマツォイティッシュ ゲゼルシャフト エムベーハー ウント コー. カーゲー 免疫抑制薬及び処置方法
WO2025056188A1 (en) 2023-09-15 2025-03-20 Relaxera Pharmazeutische Gmbh & Co. Kg Relaxin medication

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) * 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5166191A (en) 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
US5478807A (en) * 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
WO1995000645A2 (en) 1993-06-21 1995-01-05 Genentech, Inc. Process for producing relaxin
WO1995003822A2 (en) 1993-07-27 1995-02-09 Mario Bigazzi Use of relaxin as therapeutic or preventing agent
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
CA2229479C (en) * 1995-08-15 2010-03-30 Connective Therapeutics, Inc. Method of promoting angiogenesis
ATE362770T1 (de) * 2000-02-09 2007-06-15 Bas Medical Inc Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
DE10155843A1 (de) 2000-11-16 2003-01-30 Immundiagnostik Ag Verfahren zur Prognose und Diagnose von Herzinsuffizienz
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
EP1729817B1 (en) * 2004-03-30 2014-03-05 Industry-Academic Cooperation Foundation Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin
US20060264367A1 (en) * 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
US20080077025A1 (en) 2005-07-11 2008-03-27 Leticia Delgado-Herrera Methods for determining how to treat congestive heart failure
EP2167534B1 (en) 2007-07-12 2012-07-04 Compugen Ltd. Bioactive peptides and method of using same
JP5651586B2 (ja) * 2008-05-16 2015-01-14 コーセラ,インコーポレーテッド 急性心不全に伴う呼吸困難のリラキシンによる治療
RU2512933C2 (ru) 2008-05-16 2014-04-10 Кортера, Инк. Способ лечения хронической сердечной недостаточности

Similar Documents

Publication Publication Date Title
JP2016053040A5 (enExample)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MX369818B (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
MY187047A (en) Selective pyy compounds and uses thereof
JP2015057451A5 (enExample)
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
JP2016518337A5 (enExample)
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
JP2012193216A5 (enExample)
EP4609912A3 (en) New use of a combination of sacubitril and valsartan
MA37455A1 (fr) Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique
UA111599C2 (uk) Композиція каспофунгіну
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
JP2013166781A5 (enExample)
BR112017009510A2 (pt) composições compreendendo ciclosporina
BR112015007592A2 (pt) composições de enalapril
MX2016007682A (es) Composicion farmaceutica que comprende ivabradina amorfa.
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
NI201200008A (es) Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del st
JP2015516451A5 (enExample)
JP2015516450A5 (enExample)
SG10201903656RA (en) Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor
JP2017530142A5 (enExample)
NZ707033A (en) Dispersible nimorazole tablet